AU2018210397B2 - Combinations of cabozantinib and atezolizumab to treat cancer - Google Patents

Combinations of cabozantinib and atezolizumab to treat cancer Download PDF

Info

Publication number
AU2018210397B2
AU2018210397B2 AU2018210397A AU2018210397A AU2018210397B2 AU 2018210397 B2 AU2018210397 B2 AU 2018210397B2 AU 2018210397 A AU2018210397 A AU 2018210397A AU 2018210397 A AU2018210397 A AU 2018210397A AU 2018210397 B2 AU2018210397 B2 AU 2018210397B2
Authority
AU
Australia
Prior art keywords
subjects
cabozantinib
atezolizumab
dose
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018210397A
Other languages
English (en)
Other versions
AU2018210397A1 (en
Inventor
Colin Hessel
Christian SCHEFFOLD
Gisela Schwab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018210397(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2018210397A1 publication Critical patent/AU2018210397A1/en
Application granted granted Critical
Publication of AU2018210397B2 publication Critical patent/AU2018210397B2/en
Priority to AU2024203472A priority Critical patent/AU2024203472A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018210397A 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer Active AU2018210397B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203472A AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US62/448,869 2017-01-20
US201762458447P 2017-02-13 2017-02-13
US62/458,447 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203472A Division AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Publications (2)

Publication Number Publication Date
AU2018210397A1 AU2018210397A1 (en) 2019-07-25
AU2018210397B2 true AU2018210397B2 (en) 2024-02-29

Family

ID=61569414

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018210397A Active AU2018210397B2 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer
AU2024203472A Pending AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203472A Pending AU2024203472A1 (en) 2017-01-20 2024-05-24 Combinations of cabozantinib and atezolizumab to treat cancer

Country Status (15)

Country Link
US (2) US11198731B2 (https=)
EP (1) EP3570840B1 (https=)
JP (3) JP7222895B2 (https=)
KR (2) KR102610764B1 (https=)
CN (4) CN117205312A (https=)
AU (2) AU2018210397B2 (https=)
BR (1) BR112019015011A2 (https=)
CA (1) CA3049452A1 (https=)
ES (1) ES3031468T3 (https=)
IL (1) IL268138B (https=)
MA (1) MA47310A (https=)
MX (2) MX389966B (https=)
UA (1) UA126970C2 (https=)
WO (1) WO2018136796A1 (https=)
ZA (1) ZA201904652B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11198731B2 (en) * 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
IL300151A (en) * 2020-07-31 2023-03-01 Exelixis Inc Combinations for cancer treatment
WO2022040555A2 (en) * 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
WO2022197900A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2015123639A1 (en) * 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2017184597A1 (en) * 2016-04-19 2017-10-26 Exelixis, Inc. Triple negative breast cancer treatment method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
WO2014165779A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Drug combinations to treat cancer
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
US11198731B2 (en) 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2015123639A1 (en) * 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2017184597A1 (en) * 2016-04-19 2017-10-26 Exelixis, Inc. Triple negative breast cancer treatment method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kwilas, A.R., Ardiani, A., Donahue, R.N. et al. Dual effects of cabozantinib on immune-mediated killing of tumor cells and immune tumor permissiveness. J Transl Med 12, 294 (2014). https://doi.org/10.1186/s12967-014-0294-y *
Powles T et al, Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial CarcinomaEUR Urol Suppl 2017; 16(10);e2789 *

Also Published As

Publication number Publication date
ZA201904652B (en) 2024-11-27
JP2022121594A (ja) 2022-08-19
IL268138A (en) 2019-09-26
US20220056138A1 (en) 2022-02-24
AU2018210397A1 (en) 2019-07-25
MX2019008032A (es) 2019-12-16
CN117771363A (zh) 2024-03-29
ES3031468T3 (en) 2025-07-09
KR20190107103A (ko) 2019-09-18
US20190352403A1 (en) 2019-11-21
MX2022001718A (es) 2022-03-11
WO2018136796A1 (en) 2018-07-26
MA47310A (fr) 2019-11-27
EP3570840B1 (en) 2025-03-19
KR102610764B1 (ko) 2023-12-07
NZ755494A (en) 2025-06-27
BR112019015011A2 (pt) 2020-04-28
CN117205313A (zh) 2023-12-12
CA3049452A1 (en) 2018-07-26
UA126970C2 (uk) 2023-03-01
JP7222895B2 (ja) 2023-02-15
EP3570840A1 (en) 2019-11-27
IL268138B (en) 2022-08-01
MX389966B (es) 2025-03-20
CN117205312A (zh) 2023-12-12
AU2024203472A1 (en) 2024-06-13
JP2020514311A (ja) 2020-05-21
CN110352057A (zh) 2019-10-18
KR20230169458A (ko) 2023-12-15
US11198731B2 (en) 2021-12-14
JP2024019720A (ja) 2024-02-09

Similar Documents

Publication Publication Date Title
AU2018210397B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
Siegal et al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
CN110536684A (zh) 三联组合制剂以及治疗心血管疾病或降低心血管疾病风险的方法
TW202412802A (zh) 使用DGKζ抑制劑治療具有局部晚期及/或轉移性實體腫瘤之病患的方法
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40105136A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Zhang et al. Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm, phase II study
Shaw et al. Tumor Lysis Syndrome
Capdevila et al. Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Carthon Winship Protocol#: Winship4643-19 TITLE: A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
Wei A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer
No et al. Clinical trial protocol
Niemann et al. EUDRACT NUMBER: Clinicaltrials. gov number
Heist Phase II trial of cabozantinib (XL184) in patients with advanced solid (non-breast
Awan Highlights in Chronic Lymphocytic Leukemia From the 2022 American Society of Clinical Oncology Annual

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)